The pharmacodynamics of insulin are reported as peak, onset, and duration of insulins when administered. PK/PD profiles for insulin correspondents could be influenced by countless variables including age, weight, liver and kidney function. However, these variables do not have corresponding effects on all long-acting or rapid-acting insulin analogues (Table 1). The pharmacokinetics of insulin are effected in a stepwise manner through the process of drug absorption, the rate of distribution (binding to circulating insulin antibodies when available and binding to insulin receptors), and its final degradation and excretion. The distribution and metabolism of absorbed insulin follow those of endogenous insulin and these cannot be actively modified, except in the case of circulating antibodies against insulin, which in rare cases can cause insulin resistance (Christian et al., 1984 ). Pharmaceutical companies such as Sanofi-Aventis, Novo-Nordisk and Eli Lilly are belligerently marketing various forms of insulin. These companies are currently promoting the new form of insulin known as insulin analog for its function of altering the absorption, distribution, and rate of metabolism of insulin. It has been stated that some of these insulins are short acting and are therefore easily accessible. Although some drugs are known for their long-lasting action, they offer people coverage for a long period of time